Literature DB >> 27059917

Cerebrospinal Fluid Biomarkers of Simian Immunodeficiency Virus Encephalitis : CSF Biomarkers of SIV Encephalitis.

Stephanie J Bissel1, Julia Kofler2, Julia Nyaundi3, Michael Murphey-Corb3, Stephen R Wisniewski4, Clayton A Wiley2.   

Abstract

Antiretroviral therapy has led to increased survival of HIV-infected patients but also increased prevalence of HIV-associated neurocognitive disorders. We previously identified YKL40 as a potential cerebrospinal fluid (CSF) biomarker of lentiviral central nervous system (CNS) disease in HIV-infected patients and in the macaque model of HIV encephalitis. The aim of this study was to define the specificity and sensitivity along with the predictive value of YKL40 as a biomarker of encephalitis and to assess its relationship to CSF viral load. CSF YKL40 and SIV RNA concentrations were analyzed over the course of infection in 19 SIV-infected pigtailed macaques and statistical analyses were performed to evaluate the relationship to encephalitis. Using these relationships, CSF alterations of 31 neuroimmune markers were studied pre-infection, during acute and asymptomatic infection, at the onset of encephalitis, and at necropsy. YKL40 CSF concentrations above 1122 ng/ml were found to be a specific and sensitive biomarker for the presence of encephalitis and were highly correlated with CSF viral load. Macaques that developed encephalitis had evidence of chronic CNS immune activation during early, asymptomatic, and end stages of infection. At the onset of encephalitis, CSF demonstrated a rise of neuroimmune markers associated with macrophage recruitment, activation and interferon response. CSF YKL40 concentration and viral load are valuable biomarkers to define the onset of encephalitis. Chronic CNS immune activation precedes the development of encephalitis while some responses suggest protection from CNS lentiviral disease.

Entities:  

Keywords:  Biomarker; Cerebrospinal fluid; Encephalitis; Human immunodeficiency virus; Simian immunodeficiency virus; YKL40

Mesh:

Substances:

Year:  2016        PMID: 27059917      PMCID: PMC4871628          DOI: 10.1007/s11481-016-9666-9

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  90 in total

1.  Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

Authors:  Martin Gunnarsson; Clas Malmeström; Markus Axelsson; Peter Sundström; Charlotte Dahle; Magnus Vrethem; Tomas Olsson; Fredrik Piehl; Niklas Norgren; Lars Rosengren; Anders Svenningsson; Jan Lycke
Journal:  Ann Neurol       Date:  2010-12-08       Impact factor: 10.422

2.  Chemokine expression in simian immunodeficiency virus-induced AIDS encephalitis.

Authors:  V G Sasseville; M M Smith; C R Mackay; D R Pauley; K G Mansfield; D J Ringler; A A Lackner
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

3.  Opposite effects of IL-10 on the ability of dendritic cells and macrophages to replicate primary CXCR4-dependent HIV-1 strains.

Authors:  P Ancuta; Y Bakri; N Chomont; H Hocini; D Gabuzda; N Haeffner-Cavaillon
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

4.  Use of laboratory tests and clinical symptoms for identification of primary HIV infection.

Authors:  Frederick M Hecht; Michael P Busch; Bhupat Rawal; Marcy Webb; Eric Rosenberg; Melinda Swanson; Margaret Chesney; Jennifer Anderson; Jay Levy; James O Kahn
Journal:  AIDS       Date:  2002-05-24       Impact factor: 4.177

Review 5.  Considering genetic profiles in functional studies of immune responsiveness to HIV-1.

Authors:  M Carrington; G Nelson; S J O'Brien
Journal:  Immunol Lett       Date:  2001-11-01       Impact factor: 3.685

6.  Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis.

Authors:  M C Zink; G D Coleman; J L Mankowski; R J Adams; P M Tarwater; K Fox; J E Clements
Journal:  J Infect Dis       Date:  2001-09-10       Impact factor: 5.226

7.  Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.

Authors:  Yukiko Saitou; Katsuya Shiraki; Yutaka Yamanaka; Yumi Yamaguchi; Tomoyuki Kawakita; Norihiko Yamamoto; Kazushi Sugimoto; Kazumoto Murata; Takeshi Nakano
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

8.  Elevated levels of macrophage migration inhibitory factor (MIF) in the plasma of HIV-1-infected patients and in HIV-1-infected cell cultures: a relevant role on viral replication.

Authors:  Eduardo G Regis; Victor Barreto-de-Souza; Mariza G Morgado; Marcelo T Bozza; Lin Leng; Richard Bucala; Dumith C Bou-Habib
Journal:  Virology       Date:  2010-01-20       Impact factor: 3.616

9.  Early viral replication in the brain of SIV-infected rhesus monkeys.

Authors:  L Chakrabarti; M Hurtrel; M A Maire; R Vazeux; D Dormont; L Montagnier; B Hurtrel
Journal:  Am J Pathol       Date:  1991-12       Impact factor: 4.307

10.  Early viral brain invasion in iatrogenic human immunodeficiency virus infection.

Authors:  L E Davis; B L Hjelle; V E Miller; D L Palmer; A L Llewellyn; T L Merlin; S A Young; R G Mills; W Wachsman; C A Wiley
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.